Every digital health team talks about MLOps. Far fewer talk about what happens after FDA clearance. When a machine learning application supports clinical decision-making, it becomes a Software as a Medical Device under FDA jurisdiction. The infrastructure around it is a regulated activity with documentation requirements, change control obligations, and audit expectations that determine whether the product can keep operating once it is cleared.
At ITJ, we build and operate the teams that sit at that intersection. Nearshore MLOps for digital health requires a combination of pipeline engineering and compliance domain knowledge that most staffing approaches treat as separate tracks. Bringing those together from the first sprint changes what the product looks like when it reaches an inspector.
What the FDA Now Requires From ML Operations Teams
In December 2024, the FDA finalized its guidance on Predetermined Change Control Plans for AI and ML-enabled device software functions. The PCCP is the mechanism that allows a clinical AI product to evolve after market clearance without requiring a new submission for every update. It defines, in practice, how a compliant ML pipeline is allowed to operate post-clearance.
A PCCP has three required components:
- Description of Modifications: The specific changes the product may undergo, including retraining on new data, expanding to different patient populations, or adjusting performance thresholds
- Modification Protocol: The methodology for executing those changes, including validation datasets, bias analysis procedures, and benchmarks that must be met before each deployment
- Impact Assessment: How each modification will be evaluated for safety and effectiveness, and how existing users will be notified
That document does not get produced after the architecture is built. It shapes the architecture from the start. The monitoring layer, the retraining pipeline, the version control strategy, the data lineage documentation: all of it has to be designed around the modifications defined upfront. A team that builds first and documents later will find that what they built does not match what the plan requires.
When Performance Degradation Becomes a Compliance Event
In most software contexts, drift is a performance issue. An algorithm becomes less accurate. Someone updates it. No audit consequence.
In clinical AI, the same scenario carries a different weight. A sepsis prediction application trained on one hospital population may degrade when the patient mix changes, when nursing documentation practices shift, or when an EHR update alters how input variables are captured. The application continues to generate outputs. Clinicians continue to act on them. The degradation is invisible until something surfaces it, and in a governed context, what surfaces it is ideally the monitoring layer before an adverse event review.
Under FDA’s framework for Software as a Medical Device, the monitoring layer is expected to catch performance degradation before it becomes a safety issue. The FDA’s 2025 guidance on AI/ML training for regulated products requires data provenance tracking, demographic diversity analysis, and a documented Model Evolution Roadmap established at the start of the product lifecycle.
The timestamp matters. The training data provenance matters. The version of the algorithm that produced the output matters. Each of those elements has to be captured automatically, in a format that would survive an inspection, by tooling designed with that requirement in mind from the beginning. Building that monitoring layer is a different discipline than building the underlying algorithm. It requires people who understand both what the system needs to do and what the compliance record needs to show.
The Ownership Problem No One Names
Clinical AI programs rarely struggle because they lack machine learning expertise. They struggle because no single team owns both governed architecture and ML operations. Data scientists manage the models. Quality engineers manage the documentation. The pipeline that connects those two worlds, including the monitoring logic, the retraining triggers, and the audit trail that captures each modification, often belongs to neither.
In practice, that ownership gap shows up in predictable moments: a quality review that asks who owns the retraining logic, a submission that surfaces missing data lineage records, a post-market event that reveals the monitoring layer never captured what it was supposed to capture. When the technical decisions and the compliance decisions are made by the same team in the same room, those moments become manageable. When they are made separately and reconciled later, they become expensive.
Designing a compliant nearshore MLOps for digital health pipeline requires engineers who understand monitoring architecture, deployment automation, and model lifecycle management on one side, and change control documentation, 21 CFR Part 11 audit trail requirements, and PCCP-aligned validation on the other. An agile software development team built for compliant clinical AI operations has to carry both sides from the first sprint, because the architectural decisions made early determine whether the cleared product stays cleared through its commercial lifecycle.
Where ITJ Fits
The CaliBaja MedTech Corridor produces AI-ready talent in governed environments as a baseline. Engineers who develop there, through institutions like CICESE and UABC and through industry experience in medical device manufacturing and biopharma, carry the dual context this kind of engagement requires. That background shapes how they scope monitoring systems, structure change control documentation, and think about the audit implications of architectural choices from day one.
As a nearshore software engineering partner for life sciences and digital health companies, ITJ builds ML operations teams that design monitoring systems, retraining pipelines, and compliance-aligned workflows as part of the same process. Not as separate tracks that converge before a deadline.
The conversation worth having is about what your current setup would show an FDA inspector today, and whether the team maintaining it understands what that inspector would be looking for. If you are earlier in the process and evaluating how to build this capability before your first clearance, the compliance architecture is easier to build right the first time than to correct after a 510(k) or De Novo submission.
The earlier engineering and compliance decisions are aligned, the easier it becomes to scale the product, support post-market changes, reduce operational friction, and maintain regulatory confidence throughout its lifecycle. We operate in Tijuana, thirty minutes from San Diego, and are available for on-site or remote sessions. If IT services Mexico is part of your digital health staffing strategy, the compliance architecture is the right place to begin. Write to us.
Keep reading!
